May 24, 2023 09:18 AM EDT

FDA delays Sarepta's Duchenne gene therapy decision by a month

Lei Lei Wu

News Reporter

The FDA delayed its decision whether to grant accelerated approval to Sarepta Therapeutics’ gene therapy for Duchenne muscular dystrophy, pushing it back about one month …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

FDA delays Sarepta's Duchenne gene therapy decision by a month

Lei Lei Wu

News Reporter

Sign up to read this article for free.

Executive Director, Marketing

Celldex Therapeutics

Hampton, NJ, USA

Makary, in one of first comments on FDA policy, floats new pathway for rare disease drugs

China startup injects CRISPR therapy into the brain for the first time

Trodelvy and Keytruda combo succeeds in Phase 3 breast cancer study

Roivant brings rare disease program closer as Immunovant CEO retires

FDA plans to ban pharma employees from serving on adcomms. The impact will be limited

ADSTILADRIN® (nadofaragene firadenovec-vncg) – A Growing Body of Clinical Data and Real-World Evidence

FDA de­lays Sarep­ta's Duchenne gene ther­a­py de­ci­sion by a month

News Reporter

Sign up to read this article for free.

Celldex Therapeutics

Hampton, NJ, USA

FDA delays Sarepta's Duchenne gene therapy decision by a month